Journal of Neurochemistry · 1996 · 176 citations · 0 references
MedicineNeurosciencePharmacologyMolecular PharmacologyNeuropharmacologyPharmacodynamicsCholinergic PharmacologyNeurotransmissionNeurotransmitter ReceptorsReceptor PharmacologyReceptor PhysiologySynaptic TransmissionAcetylcholine PharmacologyAcetylcholine Receptor PharmacologyAntagonists Of Cholinergic ReceptorsCholinergic Receptor PharmacologyNicotinic Acetylcholine Receptor AgonismNicotinic AntagonistsNicotinic Receptor Pharmacology
Neuronal nicotinic acetylcholine receptors are differentially sensitive to blockade by the competitive antagonist dihydro-beta-erythroidine. Both alpha and beta subunits participate in determining sensitivity to this antagonist. The alpha subunit contribution to dihydro-beta-erythroidine sensitivity is illustrated by comparing the alpha 4 beta 4 receptor and the alpha 3 beta 4 receptor, which differ in sensitivity to dihydro-beta-erythroidine by approximately 120-fold. IC50 values for blocking alpha 4 beta 4 and alpha 3 beta 4, responding to EC20 concentrations of acetylcholine, were 0.19 +/- 0.06 and 23.1 +/- 10.2 microM, respectively. To map the sequence segments responsible for this difference, we constructed a series of chimeric alpha subunits containing portions of the alpha 4 and alpha 3 subunits. These chimeras were coexpressed with beta 4, allowing pharmacological characterization. We found determinants of dihydro-beta-erythroidine sensitivity to be distributed throughout the N-terminal extracellular domain of the alpha subunit. These determinants were localized to sequence segments 1-94, 94-152, and 195-215. Loss of determinants within segment 1-94 had the largest effect, decreasing dihydro-beta-erythroidine sensitivity by 4.3-fold.